ClonOrgan

The company's core business revolves around a comprehensive research and development platform that spans from the breeding of these gene-edited pigs to conducting preclinical trials. ClonOrgan provides these specialized donor pigs to medical research institutions for groundbreaking surgical procedures. For instance, the company supplied the genetically modified pigs for the world's first pig-to-human liver xenotransplantation into a brain-dead recipient in March 2024 and a subsequent kidney transplantation. In these procedures, specific pig antigens known to cause rejection were removed, and human proteins were introduced to enhance compatibility. These efforts have demonstrated the potential for the transplanted organs to function, representing significant milestones in the field of xenotransplantation.

ClonOrgan's business model is centered on supplying these highly specialized biological products and solutions to the medical industry. The company generates revenue and has secured significant venture capital funding to advance its research, including a Series A1 round in June 2024, bringing its total funding to over $8 million. By developing a future 'organ factory,' ClonOrgan aims to provide a viable and steady supply of organs for clinical applications, offering hope to hundreds of thousands of patients worldwide on transplant waiting lists.